---
document_datetime: 2025-03-20 09:40:25
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/idefirix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: idefirix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.3541969
conversion_datetime: 2025-12-28 10:31:13.127493
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Idefirix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10870 /202408  | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                     | 13/03/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| PSUSA/10870 /202402  | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                     | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| II/0024/G            | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test | 12/09/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                              |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0020              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                       | 30/05/2024 | 24/07/2024 |                   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Idefirix, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0019             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                             | 16/05/2024 | 24/07/2024 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10870 /202308 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                                                                                      | 11/04/2024 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0021/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test | 13/03/2024 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | to an approved stability protocol                                                                                                                                                                             |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0022           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                    | 08/03/2024 | 24/07/2024 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10870 /202302 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                      | 28/09/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                       | 25/05/2023 | 17/07/2023 | SmPC            | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Idefirix, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0015             | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                   | 04/05/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0013             | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability | 14/04/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0016             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                        | 12/04/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0010             | B.I.b.2.d - Change in test procedure for AS or                                                                                                                                                                | 23/03/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                      |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10870 /202208 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                                               | 16/03/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0012           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/01/2023 | 17/07/2023 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10870 /202202 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                                               | 01/09/2022 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0007              | Renewal of the marketing authorisation.                                                                                                                                                                                                | 19/05/2022 | 15/07/2022 | SmPC and PL     | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Idefirix, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0008             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                 | 05/04/2022 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10870 /202108 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                                                                                                                                                                      | 10/03/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0006/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 15/12/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10870 /202102 | Periodic Safety Update EU Single assessment - imlifidase                                                                                                                                                                                                                                                                                                      | 30/09/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                       | 20/05/2021 | 16/07/2021 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Idefirix, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0002             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                        | 29/10/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf   | 05/10/2020   | 16/07/2021   | SmPC and PL   |
|-----------|-----------------------------------------------------------|--------------|--------------|---------------|